Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Guggenheim Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $155

Author: Benzinga Newsdesk | June 18, 2024 06:37am
Guggenheim analyst Yatin Suneja initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $155.

Posted In: PRAX